Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

PI3Kδ/γ Inhibitor Duvelisib Modulates Inflammatory Profile in Severe COVID-19 Patients: Results from a Randomized Placebo-Controlled Phase 2 Study

Blood (2022) 140 (Supplement 1): 11187–11189.

https://doi.org/10.1182/blood-2022-165567

Published: 2022

Journal Articles

Duvelisib for Critically-Ill Patients with COVID-19 Disease: An Investigator-Initiated, Randomized, Placebo-Controlled Double-Blind Pilot Trial

Scott R. Goldsmith, Fahrettin Covut, Mark A. Fiala, Elizabeth Bradtke, Ayan Gasanli, Brandon Christen, Jonathan A. Pachter, Zhifu Xiang, Zahid Iqbal, Nathan Moore, Uchenna Ofoma, Bijal Parikh, Erik Dubberke, John F. DiPersio

Blood (2022) 140 (Supplement 1): 11185–11186.

https://doi.org/10.1182/blood-2022-157605

Published: 2022

Journal Articles

The Dual PI3Kdg Inhibitor Duvelisib Potently Inhibits Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function

Parmeshwar N. Amatya, Reyka G. Jayasinghe, Alun J. Carter, Matthew L. Cooper, Jonathan A. Pachter, John F. DiPersio, Julie K. Ritchey

Blood (2022) 140 (Supplement 1): 12686–12687.

https://doi.org/10.1182/blood-2022-167715

Published: 2022

Journal Articles

PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity

Christopher Ronald Funk, Shuhua Wang, Kevin Z. Chen, Alexandra Waller, Aditi Sharma, Claudia L. Edgar, Vikas A. Gupta, Shanmuganathan Chandrakasan, Jaquelyn T. Zoine, Andrew Fedanov, Sunil S. Raikar, Jean L. Koff, Christopher R. Flowers, Silvia Coma, Jonathan A. Pachter, Sruthi Ravindranathan, H. Trent Spencer, Mala Shanmugam, Edmund K. Waller

Blood (2022) 139 (4): 523–537.

https://doi.org/10.1182/blood.2021011597

Published: 2022

Includes: Supplemental data

Journal Articles

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Andrea Iannello, Nicoletta Vitale, Silvia Coma, Francesca Arruga, Amy Chadburn, Arianna Di Napoli, Carlo Laudanna, John N. Allan, Richard R. Furman, Jonathan A. Pachter, Silvia Deaglio, Tiziana Vaisitti

Blood (2021) 137 (24): 3378–3389.

https://doi.org/10.1182/blood.2020010187

Published: 2021

Includes: Supplemental data

Journal Articles

Macrophage Activation By Dual PI3K-δ/γ Inhibition Enhances Anti-CD47-Mediated Phagocytosis and Prolongs Survival in DLBCL

James Godfrey, MD, Wenjun Kang, MS, Lei Huang, PhD, Silvia Coma, PhD, Roy Maute, PhD, Mark P. Chao, MD PhD, Jonathan A Pachter, PhD, Sonali Smith, MD, Justin Kline, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-143304

Published: 2020

Journal Articles

The Dual PI3Kδγ Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo

Parmeshwar N Amatya, PhD, Alun J Carter, PhD BSc, Julie K Ritchey, Jessica Niswonger, Matthew L Cooper, PhD, Jonathan A Pachter, PhD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139904

Published: 2020

Journal Articles

The Dual PI3K-δ/γ Inhibitor Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax Shows Promising Responses in Richter Syndrome-PDX Models

Andrea Iannello, PhD, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Elisa Marchi, Richard R. Furman, MD, John N. Allan, MD, Silvia Coma, PhD, Jonathan A. Pachter, PhD, Silvia Deaglio, MD PhD, Tiziana Vaisitti, PhD

Blood (2019) 134 (Supplement_1): 2862.

https://doi.org/10.1182/blood-2019-125754

Published: 2019

Journal Articles

Dual Inhibition of PI3K-δ and PI3K-γ By Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Patient-Derived Xenograft Model

Shih-Shih Chen, PhD, Jeffery Lorne Kutok, MD PhD, Gerardo Ferrer, PhD, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, MSCR, Jacqueline C Barrientos, MD MS, David T. Weaver, PhD, Jonathan A Pachter, PhD, Kanti R Rai, MD, Nicholas Chiorazzi, MD

Blood (2018) 132 (Supplement 1): 4420.

https://doi.org/10.1182/blood-2018-99-109853

Published: 2018

Journal Articles

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMO TM Clinical Trial in iNHL

Pier Luigi Zinzani, MD, Ian W. Flinn, MD PhD, Carole B. Miller, MD, Scott A. Tetreault, MD, Kirit M. Ardeshna, MBBChir, NgocDiep Le, MD PhD, Jonathan A. Pachter, PhD, Kam Sprott, PhD, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Nina D. Wagner-Johnston, MD

Blood (2018) 132 (Supplement 1): 4167.

https://doi.org/10.1182/blood-2018-99-117903

Published: 2018

Journal Articles

Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUO TM Study

Jennifer R. Brown, MD PhD, Ian W. Flinn, MD PhD, Matthew S. Davids, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Marco Montillo, MD, Zsolt Nagy, MD PhD, Julio Delgado, MD, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Ulrich Jaeger, MD, Paolo Ghia, MD PhD, Stephan Stilgenbauer, Carol Moreno, MD PhD, NgocDiep Le, MD PhD, Stephanie Lustgarten, PhD, Kam Sprott, PhD, Jonathan A. Pachter, PhD, David T. Weaver, PhD, Florence Cymbalista, MD PhD

Blood (2018) 132 (Supplement 1): 1856.

https://doi.org/10.1182/blood-2018-99-114251

Published: 2018

Journal Articles

Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 in AML

Xiangmeng Wang, PhD, Po Yee Mak, Hong Mu, MD PhD, Wenjing Tao, PhD, Jonathan A Pachter, PhD, David T Weaver, PhD, Bing Xu, Michael Andreeff, MD PhD, Bing Z Carter, PhD

Blood (2017) 130 (Supplement 1): 2653.

https://doi.org/10.1182/blood.V130.Suppl_1.2653.2653

Published: 2017

Journal Articles

The Dual PI3K-δ,γ Inhibitor Duvelisib Stimulates Anti-Tumor Immunity and Enhances Efficacy of Immune Checkpoint and Co-Stimulatory Antibodies in a B Cell Lymphoma Model

Jonathan A Pachter, PhD, David T Weaver, PhD

Blood (2017) 130 (Supplement 1): 1541.

https://doi.org/10.1182/blood.V130.Suppl_1.1541.1541

Published: 2017

Journal Articles

Inhibition of FAK Exerts Anti-Leukemic Activity and Potentiates ABT-199-Induced Apoptosis in AML

Xiangmeng Wang, Po Yee Mak, MPhil, Hong Mu, MD PhD, Xuejie Jiang, Duncan Mak, BSc, MPhil, Jonathan A. Pachter, PhD, David T. Weaver, PhD, Bing Xu, PhD, Michael Andreeff, MD PhD, Bing Z Carter, PhD

Blood (2016) 128 (22): 1574.

https://doi.org/10.1182/blood.V128.22.1574.1574

Published: 2016

Journal Articles

Efficacy of Focal Adhesion Kinase Inhibition in Combination with Dasatinib in BCR-ABL1 Acute Lymphoblastic Leukemia

Michelle L. Churchman, PhD, Luke Jones, BSc(Hons), Kathryn Evans, BSc(Hons), Jennifer Richmond, BSc(Hons), Irina M Shapiro, PhD, Jonathan A. Pachter, PhD, David T. Weaver, PhD, Peter J Houghton, PhD, Malcolm A. Smith, MD PhD, Richard B Lock, PhD, Charles G. Mullighan, MBBS, MSc, MD

Blood (2015) 126 (23): 3766.

https://doi.org/10.1182/blood.V126.23.3766.3766

Published: 2015

Journal Articles

Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death

Mark B Meads, PhD, Bin Fang, PhD, Linda Mathews, Jennifer Gemmer, MS, Liang Nong, MD, Ismael Rosado-Lopez, Tuan Nguyen, Jennifer E. Ring, William Matsui, MD, Robert MacLeod, PhD, David T. Weaver, PhD, Jonathan A. Pachter, PhD, Lori A. Hazlehurst, PhD, John M. Koomen, PhD, Kenneth H. Shain, MD PhD

Blood (2015) 126 (23): 3008.

https://doi.org/10.1182/blood.V126.23.3008.3008

Published: 2015

Journal Articles

Focal Adhesion Kinase Inhibitors Reverse the Stromal Adhesion Phenotype of Ikaros-Mutant B-ALL, Induce Apopotosis, and Synergize with ABL1 Tyrosine Kinase Inhibitors: A New Paradigm for Pathogenesis and Therapy of High-Risk B-ALL

Ila Joshi, PhD, Nilamani Jena, PhD, Toshimi Yoshida, PhD, Leto Paraskevopoulou, BS, Zhihong Zhang, PhD, Zhong-Ying Liu, MDPhD, Shane Korber, Daniela S. Krause, MD, Irina M. Shapiro, PhD, David T. Weaver, PhD, Jonathan A. Pachter, PhD, Elisabeth M. Paietta, PhD, Richard A. Van Etten, MDPhD, Katia Georgopoulos, PhD

Blood (2014) 124 (21): 285.

https://doi.org/10.1182/blood.V124.21.285.285

Published: 2014

Journal Articles

VS-4718, a Potent Focal Adhesion Kinase (FAK) Inhibitor, Exhibits Anticancer Activity in Leukemia Models in Vitro and in Vivo

Winnie F. Tam, PhD, Jennifer E. Ring, Anthony F. Trombino, PhD, David T. Weaver, PhD, Jonathan A. Pachter, PhD, Mahesh Padval, PhD, Qunli Xu, PhD

Blood (2014) 124 (21): 982.

https://doi.org/10.1182/blood.V124.21.982.982

Published: 2014

Journal Articles

Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death

Kenneth H. Shain, MD PhD, Mark B Meads, PhD, Bin Fang, PhD, Linda Mathews, Jennifer Gemmer, Liang Nong, MD, Ismael Rosado-Lopez, BS, Jennifer E. Ring, Robert MacLeod, PhD, Lori Hazlehurst, PhD, Conor Lynch, PhD, Jonathan A. Pachter, PhD, William Matsui, MD, John Koomen, PhD, Tuan Nguyen

Blood (2014) 124 (21): 2081.

https://doi.org/10.1182/blood.V124.21.2081.2081

Published: 2014

Journal Articles

Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression in Multiple Myeloma (MM) and Represents a Novel Target for Therapy in MM

Yu Zhang, MD, Yong Zhang, PhD, Yuji Mishima, PhD, Michele Moschetta, MD, Wenjing Zhang, MD, Patricia Maiso, PhD, Antonio Sacco, BS, Yosra Aljawai, MS, Ilyas Sahin, MD, Michaela R. Reagan, PhD, Jennifer E. Ring, Winnie F. Tam, PhD, Qunli Xu, PhD, Jonathan A. Pachter, PhD, Aldo M Roccaro, MD PhD, Irene M. Ghobrial, MD

Blood (2014) 124 (21): 2101.

https://doi.org/10.1182/blood.V124.21.2101.2101

Published: 2014

NARROW

PI3Kδ/γ Inhibitor Duvelisib Modulates Inflammatory Profile in Severe COVID-19 Patients: Results from a Randomized Placebo-Controlled Phase 2 Study

Duvelisib for Critically-Ill Patients with COVID-19 Disease: An Investigator-Initiated, Randomized, Placebo-Controlled Double-Blind Pilot Trial

The Dual PI3Kdg Inhibitor Duvelisib Potently Inhibits Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function

PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Macrophage Activation By Dual PI3K-δ/γ Inhibition Enhances Anti-CD47-Mediated Phagocytosis and Prolongs Survival in DLBCL

The Dual PI3Kδγ Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo

The Dual PI3K-δ/γ Inhibitor Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax Shows Promising Responses in Richter Syndrome-PDX Models

Dual Inhibition of PI3K-δ and PI3K-γ By Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Patient-Derived Xenograft Model

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMO TM Clinical Trial in iNHL

Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUO TM Study

Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 in AML

The Dual PI3K-δ,γ Inhibitor Duvelisib Stimulates Anti-Tumor Immunity and Enhances Efficacy of Immune Checkpoint and Co-Stimulatory Antibodies in a B Cell Lymphoma Model

Inhibition of FAK Exerts Anti-Leukemic Activity and Potentiates ABT-199-Induced Apoptosis in AML

Efficacy of Focal Adhesion Kinase Inhibition in Combination with Dasatinib in BCR-ABL1 Acute Lymphoblastic Leukemia

Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death

Focal Adhesion Kinase Inhibitors Reverse the Stromal Adhesion Phenotype of Ikaros-Mutant B-ALL, Induce Apopotosis, and Synergize with ABL1 Tyrosine Kinase Inhibitors: A New Paradigm for Pathogenesis and Therapy of High-Risk B-ALL

VS-4718, a Potent Focal Adhesion Kinase (FAK) Inhibitor, Exhibits Anticancer Activity in Leukemia Models in Vitro and in Vivo

Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death

Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression in Multiple Myeloma (MM) and Represents a Novel Target for Therapy in MM

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only